The FDA's myopic focus on early-stage testing and lack of emphasis on phase four human clinical trials has led to many safety-related drug recalls in recent years, meriting a reexamination of our regulatory system.
Paul Greenberg, author of the new book Four Fish: the Future of the Last Wild Food, discusses humanity's changing relationship with the oceans in this podcast interview and book review.
In their new book Merchants of Doubt, Naomi Oreskes and Erik Conway document how the cast of characters peddling pseudo-science had been stunningly consistent over the years, from secondhand smoke skeptics to “Star Wars” missile defense proponents to modern climate science deniers.
The Food and Drug Administration approves the first clinical trial for embryonic stem cell treatment in patients with recent spinal cord injuries—creating a much needed regulatory pathway.
The massive environmental damage requires a systematic approach to the analysis of public policy priorities and the costs BP must bear over the long term.
The federal government should partner with venture capitalists to help our nation’s innovative small businesses build the equity capital they need to grow and prosper in the United States.
The idea of informed consent has grown up, and it’s time to rethink the reasoning behind the consent system for tissue donation, writes Jonathan Moreno.
Public policy makers need to manage the risks and rewards of this promising new life sciences industry, particularly with an eye on the global context.
Ethics concerns arise about testing company 23andMe’s genetic data-gathering efforts prior to the publication of a key research paper by the company.
A pilot initiative from the federal government could accelerate the great potential of breakthrough innovations arising from academic research.
A new study points to the possibility that retina cells can be derived from embryonic stem cells, but new regulatory procedures need to be in place to oversee the research going forward.
The true measure of a clinical trial’s worth is not whether it provides dying patients access to unproven medications, but rather, whether it produces a bountiful yield of knowledge that empowers future healthcare providers.
Critics of synthetic biology who fear that scientists are overstepping boundaries should have raised their objections in the 19th century.
Pollution in coastal waters around the country has damaged shellfish habitats for decades, but promising restoration programs can preserve the tiny bivalves that are crucial to healthy waters along our shorelines.
The emerging technology is cause for celebration but risks overreaction that could inhibit innovation.
For the networks of scholars who study innovation to fully understand the process, they must examine innovation in a networked world.
This Science Progress newsletter will go on hiatus for the summer as we transition staff. We will alert you as soon as it starts up again, but expect a period of radio (or, rather, email) silence. You can continue to find new content right here on the Science Progress homepage, and can get automated updates through our RSS feed.
After almost three years on the project, your humble managing editor will be moving on to join Teach for America’s teacher training program. It’s been a pleasure, an honor, and a remarkable educational experience bringing to you, our readers, progressive ideas about how science strengthens the United States, and vice versa. Thank you all. —Andrew Pratt
© Center for American Progress
Science Progress is a Project of
